Press Releases

BRISBANE, Calif. , July 13, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focusing on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that the landmark

PAMA to provide pricing certainty for high value diagnostic testing

CareDx further bolsters clinical evidence

Late-breaking DART data presented at ASN meeting in Chicago

Defines Cell-free DNA Levels in Stable Kidney Transplant Patients

Cell-free-DNA test identifies active rejection in kidney transplant patients

CareDx at the Forefront of Personalized Medicine in Transplantation CareDx to hold Conference Call on June 13, 2016 at 4pm ET BRISBANE, Calif. , June 13, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization

BRISBANE, Calif. , May 04, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA) announces that Palmetto GBA has released a draft local coverage determination (LCD) for AlloSure. AlloSure is the first and only non-invasive test that uses donor derived cell free DNA as a biomarker to directly measure

BRISBANE, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight the first and only

BRISBANE, Calif. , May 30, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight CareDx's Olerup